Abstract
ObjectivesTo identify and validate a biomarker panel by serum metabolic profiling for improvement of PCa diagnosis.Materials and MethodsTotally, 134 individuals were included in this study. Among them, 39 PCa patients and 45 control patients (negative prostate biopsy) were involved in the discovery phase and 50 healthy controls were enrolled for validation phase of metabolomics study. LC-MS Analysis was used for the identification of the serum metabolites of patients.ResultsLogistics regression analysis shows that 5 metabolites [dMePE(18:0/18:2), PC(16:0/20:2), PS(15:0/18:2), SM(d16:0/24:1], Carnitine C14:0) were significantly changed in PCa patients compared with control patients. A metabolic panel (MET) was calculated, showing a significantly higher diagnostic performance than PSA in differentiating PCa from control patients [AUC (MET vs. PSA): 0.823 ± 0.046 vs. 0.712 ± 0.057, p<0.001]. Moreover, this panel was superior to PSA in distinguishing PCa from negative prostate biopsies when PSA levels were less than 20 ng/ml [AUC (MET vs. PSA]: 0.836 ± 0.050 vs. 0.656 ± 0.067, p<0.001]. In the validation set, the MET panel yielded an AUC of 0.823 in distinguishing PCa patients from healthy controls, showing a significant improvement of PCa detection.ConclusionsThe metabolite biomarker panel discovered in this study presents a good diagnostic performance for the detection of PCa.
Highlights
Prostate cancer (PCa) is the second most common malignant tumor in the male worldwide [1]
The early detection mainly depends on the level of prostate specific antigen (PSA) followed by prostate biopsy which is the gold standard for the PCa
The use of nanoflow liquid chromatography-mass spectrometry makes it possible to do the profiling of the glycans and the glycolipids which can be used in the clinic studies, including glycan-based biomarker discovery and therapeutics
Summary
Prostate cancer (PCa) is the second most common malignant tumor in the male worldwide [1]. The early detection mainly depends on the level of prostate specific antigen (PSA) followed by prostate biopsy which is the gold standard for the PCa. Serum Metabolic Profiling in PCa diagnosis. The peripheral blood based liquid biopsy is a powerful tool being used for the discovery of novel biomarkers for many diseases, including malignant tumors. It provides evidences for the better understanding of the initiation and development of diseases. Metabolic factors themselves are able to change the disease progression [6] In this way, the serum metabolite is the result and the reason for cancer development. The use of nanoflow liquid chromatography-mass spectrometry (nanoLC-MS) makes it possible to do the profiling of the glycans and the glycolipids which can be used in the clinic studies, including glycan-based biomarker discovery and therapeutics
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
